Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Upgraded by Wedbush

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by equities researchers at Wedbush to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other analysts also recently issued reports on the stock. Citizens Jmp dropped their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Morgan Stanley began coverage on shares of Kalaris Therapeutics in a report on Thursday, April 16th. They set an “overweight” rating and a $14.00 price objective for the company. Finally, Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.60.

Kalaris Therapeutics Stock Performance

NASDAQ KLRS opened at $5.22 on Thursday. Kalaris Therapeutics has a 52-week low of $2.14 and a 52-week high of $11.88. The company has a market capitalization of $120.02 million, a P/E ratio of -2.43 and a beta of 0.15. The company has a fifty day moving average of $6.58 and a 200-day moving average of $7.52.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. As a group, analysts forecast that Kalaris Therapeutics will post -2.15 EPS for the current fiscal year.

Institutional Trading of Kalaris Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. WHI TRUST Co LLC bought a new stake in Kalaris Therapeutics in the fourth quarter worth $823,000. Belpointe Asset Management LLC bought a new stake in Kalaris Therapeutics in the third quarter worth $231,000. Fortis Capital Advisors LLC bought a new stake in Kalaris Therapeutics in the third quarter worth $231,000. Marshall Wace LLP lifted its stake in Kalaris Therapeutics by 416.3% in the fourth quarter. Marshall Wace LLP now owns 72,876 shares of the company’s stock worth $615,000 after purchasing an additional 58,761 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in Kalaris Therapeutics by 52.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 34,303 shares of the company’s stock worth $290,000 after purchasing an additional 11,838 shares during the last quarter. 66.05% of the stock is owned by institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.